[go: up one dir, main page]

PE20000547A1 - Combinacion de fentolamina e inhibidores de fosfodiesterasa gmp ciclicos para el tratamiento de la disfuncion sexual - Google Patents

Combinacion de fentolamina e inhibidores de fosfodiesterasa gmp ciclicos para el tratamiento de la disfuncion sexual

Info

Publication number
PE20000547A1
PE20000547A1 PE1999000419A PE00041999A PE20000547A1 PE 20000547 A1 PE20000547 A1 PE 20000547A1 PE 1999000419 A PE1999000419 A PE 1999000419A PE 00041999 A PE00041999 A PE 00041999A PE 20000547 A1 PE20000547 A1 PE 20000547A1
Authority
PE
Peru
Prior art keywords
phentholamine
treatment
sexual dysfunction
fentholamine
combination
Prior art date
Application number
PE1999000419A
Other languages
English (en)
Inventor
Thomas Mark Estok
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20000547A1 publication Critical patent/PE20000547A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)MESILATO DE FENTOLAMINA; b)UN INHIBIDOR DE 3`,5'-MONOFOSFATO DE FOSFODIESTERASA GUANOSINA CICLICA TIPO V (PDE cGMPV), SIENDO DE PREFERENCIA CITRATO DE SILDENAFILO, (6R, 12aR)-2,3,6,7,12,12a-HEXAHIDRO-2-METIL-6-(3,4-METILENDIOXIFENIL)-PIRAZINO[2'1':6,1]PIRIDO[3,4-b]INDOL-1,4-DIONA, (3S,6R,12aR)-2,3,6,7,12,12a-HEXAHIDRO-2,3-DIMETIL-6-(3,4-METILENDIOXIFENIL)-PIRAZINO[2',1':6,1]PIRIDO[3,4-b]-INDOL-1,4-DIONA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN PRIMER Y UN SEGUNDO AGENTE VASODILATADOR; EL PRIMER AGENTE ES UN AGENTE DE BLOQUEO ALFA-1 ADRENERGICO O ALFA-2 ADRENERGICO TAL COMO FENTOLAMINA, MESILATO DE FENTOLAMINA, CLORHIDRATO DE FENTOLAMINA, FENOXIBENZAMINA, TOLAZOLINA, DIBENAMINA, YOHIMBINA, TERAZOSINA, DOXAZOSINA, PRAZOSINA. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DISFUNCION SEXUAL
PE1999000419A 1998-05-20 1999-05-18 Combinacion de fentolamina e inhibidores de fosfodiesterasa gmp ciclicos para el tratamiento de la disfuncion sexual PE20000547A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8164098A 1998-05-20 1998-05-20
US8297798A 1998-05-21 1998-05-21
US10651798A 1998-06-29 1998-06-29

Publications (1)

Publication Number Publication Date
PE20000547A1 true PE20000547A1 (es) 2000-07-15

Family

ID=27374039

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000419A PE20000547A1 (es) 1998-05-20 1999-05-18 Combinacion de fentolamina e inhibidores de fosfodiesterasa gmp ciclicos para el tratamiento de la disfuncion sexual

Country Status (3)

Country Link
AU (1) AU4068599A (es)
PE (1) PE20000547A1 (es)
WO (1) WO1999059584A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161255A4 (en) * 1999-03-08 2002-07-17 Merck & Co Inc METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION
IL135817A0 (en) * 1999-04-30 2001-05-20 Lilly Icos Llc Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
BRPI0003386B8 (pt) 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
WO2007014929A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
BRPI0716436B8 (pt) 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146249T3 (es) * 1993-02-10 2000-08-01 Bmra Corp Bv Composicion farmaceutica para tratar la impotencia que contiene un inhibidor alfa-1 y un inhibidor alfa-2.
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments

Also Published As

Publication number Publication date
WO1999059584A1 (en) 1999-11-25
AU4068599A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
PE20000547A1 (es) Combinacion de fentolamina e inhibidores de fosfodiesterasa gmp ciclicos para el tratamiento de la disfuncion sexual
TR200200989T2 (tr) Farmasötik açıdan aktif bileşikler.
MA29885B1 (fr) 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidine -5-ones
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
TR200003039T2 (tr) Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri
WO2006000922A3 (en) 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
AR022665A1 (es) Compuestos farmaceuticamente activos
LU92323I2 (fr) La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate
DK1646389T3 (da) Pyrimidin-2,4-dionderivater som gonadotropinfrigörende hormonreceptorantagonister
MY130681A (en) Compositions and methods for treating female sexual dysfunction
IN2012DN06436A (es)
TNSN05176A1 (fr) Derives de diazepino-indole servant d'inhibiteurs de kinases
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
PE20000702A1 (es) Formulaciones intranasales para tratar trastornos sexuales
IL164491A0 (en) Non nucleoside reverse transcriptase inhibitors
PE20010924A1 (es) Compuestos inhibidores de fosfodiesterasa utiles para el tratamiento de la disfuncion sexual femenina
AR027464A1 (es) Oxamidas que son inhibidores de la inosina monofosfato deshidrogenasa (impdh)
BRPI0412327A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
WO2003022805A3 (en) Heterocycle substituted purines as antiproliferative agents
WO2002000657A3 (en) Condensed pyrazindione derivatives
PT102457A (pt) Composicao farmaceutica contendo um inibidor selectivo de pde5
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
NO20002696L (no) Nye forbindelser med cGMP-PDE-inhibitoreffekt
AR038858A1 (es) Combinacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal